Novel multi-target ligands of dopamine and serotonin receptors for the treatment of schizophrenia based on indazole and piperazine scaffolds–synthesis, biological activity, and structural evaluation

References

• Bakhshi K, Chance SA. Neuroscience. 2015;303:82–102.
   PubMed Web of Science ®Google Scholar
• Stępnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Molecules. 2018;23(8):2087.
   PubMed Web of Science ®Google Scholar
• “Schizophrenia”. World Health Organization; 2016 [accessed 2016 Apr] [Internet]. http://www.who.int/mediacentre/factsheets/fs397/en/.
   Google Scholar
• Marder SR, Cannon TD. Schizophrenia. N Engl J Med. 2019;381(18):1753–1761.
   PubMed Web of Science ®Google Scholar
• Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophr Bull. 2009;35(3):549–562.
   PubMed Web of Science ®Google Scholar
• Kane JM. A new treatment paradigm: targeting trace amine-associated receptor 1 (TAAR1) in schizophrenia. J Clin Psychopharmacol. 2022;42(5 Suppl. 1):S1–S13.
   PubMed Web of Science ®Google Scholar
• Miller GM. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J Neurochem. 2011;116(2):164–176.
   PubMed Web of Science ®Google Scholar
• Tonelli M. The breakthrough of TAAR1 agonists for the treatment of neuropsychiatric disorders: one step away. Curr Med Chem. 2022;29(29):4893–4895.
   PubMed Web of Science ®Google Scholar
• Ginovart N, Kapur S. Role of dopamine D(2) receptors for antipsychotic activity. Handb Exp Pharmacol. 2012;(212):27–52.
   Google Scholar
• Lameh J, Burstein ES, Taylor E, Weiner DM, Vanover KE, Bonhaus DW. Pharmacology of N-desmethylclozapine. Pharmacol Ther. 2007;115(2):223–231.
   PubMed Web of Science ®Google Scholar
• Kondej M, Stępnicki P, Kaczor AA. Multi-target approach for drug discovery against schizophrenia. Int J Mol Sci. 2018;19(10):3105.
   PubMed Web of Science ®Google Scholar
• Kaczor AA, Targowska-Duda KM, Stępnicki P, Silva AG, Koszła O, Kędzierska E, Grudzińska A, Kruk-Słomka M, Biała G, Castro M. N-(3-{4-[3-(trifluoromethyl)phenyl]piperazin-1-yl}propyl)-1H-indazole-3-carboxamide (D2AAK3) as a potential antipsychotic: in vitro, in silico and in vivo evaluation of a multi-target ligand. Neurochem Int. 2021;146:105016.
   PubMed Web of Science ®Google Scholar
• Gibson MS, Bradshaw RW. The Gabriel synthesis of primary amines. Angew Chem Int Ed Engl. 1968;7(12):919–930.
   Web of Science ®Google Scholar
• Fukuyama K, Motomura E, Okada M. Therapeutic potential and limitation of serotonin type 7 receptor modulation. Int J Mol Sci. 2023;24(3):2070.
   PubMed Web of Science ®Google Scholar
• Ballesteros JA, Weinstein H. Integrated methods for the construction of three-dimensional models and computational probing of structure–function relations in G protein-coupled receptors. In: Sealfon SC, editor. Methods in Neurosciences. Vol. 25. Academic Press; 1995. p. 366–428.
   Google Scholar
• Groom CR, Bruno IJ, Lightfoot MP, Ward SC. The Cambridge Structural Database. Acta Crystallogr B Struct Sci Cryst Eng Mater. 2016;72(Pt 2):171–179.
   PubMedGoogle Scholar
• Allen FH, Watson DG, Brammer L, Orpen AG, Taylor R. Typical interatomic distances: organic compounds. In: Prince E, editor. International Tables for Crystallography Volume C: Mathematical, physical and chemical tables. Dordrecht: Springer; 2006. p. 790–811.
   Google Scholar
• Moraski GC, Oliver AG, Markley LD, Cho S, Franzblau SG, Miller MJ. Scaffold-switching: an exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates. Bioorg Med Chem Lett. 2014;24(15):3493–3498.
   PubMed Web of Science ®Google Scholar
• Kuang S, Zhang P, Dong EZ, Jennings G, Zhao B, Pierce M. Crystal form control and particle size control of RG3487, a nicotinic α7 receptor partial agonist. Int J Pharm. 2016;508(1–2):109–122.
   PubMedGoogle Scholar
• Enguehard-Gueiffier C, Hübner H, El Hakmaoui A, Allouchi H, Gmeiner P, Argiolas A, Melis MR, Gueiffier A. 2-[(4-Phenylpiperazin-1-yl)methyl]imidazo(di)azines as selective D4-ligands. Induction of penile erection by 2-[4-(2-methoxyphenyl)piperazin-1-ylmethyl]imidazo[1,2-a]pyridine (PIP3EA), a potent and selective D4 partial agonist. J Med Chem. 2006;49(13):3938–3947.
   PubMed Web of Science ®Google Scholar
• Żesławska E, Szymańska E, Nitek W, Handzlik J. Crystallographic studies of piperazine derivatives of 3-methyl-5-spiro­fluorenehydantoin in search of structural features of P-gp inhibitors. Acta Crystallogr C Struct Chem. 2021;77(Pt 8):467–478.
   PubMedGoogle Scholar
• Bosc J-J, Jarry C, Léger J-M, Carpy A. NMR and crystallographic evidence for polymorphism of the N-phenyl-N′-[1-(3-(phenyl-4-piperazinyl)propan-2-ol)]urea. J Chem Crystallogr. 1996;26(12):807–814.
   Web of Science ®Google Scholar
• Şahin ZS, Yarım M, Köksal M. Density functional computational and X-ray studies on pharmaceutical compound 1-{3-[4-(4-fluorophenyl)piperazin-1-yl]propyl}-1H-indole. Eur J Chem. 2017;8(1):1–7.
   Google Scholar
• Kossakowski J, Hejchman E, Wolska I. Synthesis and structural characterization of aminoalkanol derivatives of 2,3-dihydro-2,2-dimethyl-7-benzofuranol with an expected β-adrenolytic and/or anxiolytic activity. Z Für Naturforschung B. 2002;57(3):285–294.
   Google Scholar
• Xu W, Jiang R, Yuan M. Synthesis, crystal structure, biological evaluation, and molecular docking studies of quinoline-arylpiperazine derivative as potent α1A-adrenoceptor antagonist. J Mol Struct. 2017;1130:895–900.
   Web of Science ®Google Scholar
• Bernstein J, Davis RE, Shimoni L, Chang N-L. Patterns in hydrogen bonding: functionality and graph set analysis in crystals. Angew Chem Int Ed Engl. 1995;34(15):1555–1573.
   Web of Science ®Google Scholar
• Cremer D, Pople JA. General definition of ring puckering coordinates. J Am Chem Soc. 1975;97(6):1354–1358.
   Web of Science ®Google Scholar
• Boeyens JCA. The conformation of six-membered rings. J Cryst Mol Struct. 1978;8(6):317–320.
   Web of Science ®Google Scholar
• Haasnoot CAG. The conformation of six-membered rings described by puckering coordinates derived from endocyclic torsion angles. J Am Chem Soc. 1992;114(3):882–887.
   Web of Science ®Google Scholar
• Gobira PH, Ropke J, Aguiar DC, Crippa JAS, Moreira FA. Animal models for predicting the efficacy and side effects of antipsychotic drugs. Rev Bras Psiquiatr. 2013;35(Suppl. 2):S132–S139.
   PubMedGoogle Scholar
• Costall B, Domeney AM, Naylor RJ. Locomotor hyperactivity caused by dopamine infusion into the nucleus accumbens of rat brain: specificity of action. Psychopharmacology. 1984;82(3):174–180.
   PubMed Web of Science ®Google Scholar
• Cools AR. Mesolimbic dopamine and its control of locomotor activity in rats: differences in pharmacology and light/dark periodicity between the olfactory tubercle and the nucleus accumbens. Psychopharmacology. 1986;88(4):451–459.
   PubMed Web of Science ®Google Scholar
• Kołaczkowski M, Mierzejewski P, Bienkowski P, Wesołowska A, Newman-Tancredi A. Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia. Naunyn Schmiedebergs Arch Pharmacol. 2014;387(6):545–557.
   PubMed Web of Science ®Google Scholar
• Zhang G, Stackman RW. The role of serotonin 5-HT2A receptors in memory and cognition. Front Pharmacol. 2015;6:225.
   PubMed Web of Science ®Google Scholar
• Overstreet DH, Commissaris RC, De La Garza R, File SE, Knapp DJ, Seiden LS. Involvement of 5-HT1A receptors in animal tests of anxiety and depression: evidence from genetic models. Stress. 2003;6(2):101–110.
   PubMed Web of Science ®Google Scholar
• Heisler LK, Chu H-M, Brennan TJ, Danao JA, Bajwa P, Parsons LH, Tecott LH. Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci U S A. 1998;95(25):15049–15054.
   PubMed Web of Science ®Google Scholar
• Andrews N, Hogg S, Gonzalez LE, File SE. 5-HT1A receptors in the median raphe nucleus and dorsal hippocampus may mediate anxiolytic and anxiogenic behaviours respectively. Eur J Pharmacol. 1994;264(3):259–264.
   PubMed Web of Science ®Google Scholar
• Selent J, Marti-Solano M, Rodríguez J, Atanes P, Brea J, Castro M, Sanz F, Loza MI, Pastor M. Novel insights on the structural determinants of clozapine and olanzapine multi-target binding profiles. Eur J Med Chem. 2014;77:91–95.
   PubMed Web of Science ®Google Scholar
• Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol. 1998;54(1):94–104.
   PubMed Web of Science ®Google Scholar
• Kaczor AA, Targowska-Duda KM, Silva AG, Kondej M, Biała G, Castro M. N-(2-hydroxyphenyl)-1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]piperidine-4-carboxamide (D2AAK4), a multi-target ligand of aminergic GPCRs, as a potential antipsychotic. Biomolecules. 2020;10(2):349.
   PubMed Web of Science ®Google Scholar
• Kaczor AA, Silva AG, Loza MI, Kolb P, Castro M, Poso A. Structure-based virtual screening for dopamine D2 receptor ligands as potential antipsychotics. ChemMedChem. 2016;11(7):718–729.
   PubMed Web of Science ®Google Scholar
• Leff P, Dougall IG. Further concerns over Cheng-Prusoff analysis. Trends Pharmacol Sci. 1993;14(4):110–112.
   PubMed Web of Science ®Google Scholar
• Schrödinger release 2021–4: LigPrep. New York (NY): Schrödinger, LLC; 2021.
   Google Scholar
• Schrödinger release 2021–4: Epik. New York (NY): Schrödinger, LLC; 2021.
   Google Scholar
• Greenwood JR, Calkins D, Sullivan AP, Shelley JC. Towards the comprehensive, rapid, and accurate prediction of the favorable tautomeric states of drug-like molecules in aqueous solution. J Comput Aided Mol Des. 2010;24(6–7):591–604.
   PubMed Web of Science ®Google Scholar
• Wang S, Che T, Levit A, Shoichet BK, Wacker D, Roth BL. Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone. Nature. 2018;555(7695):269–273.
   PubMed Web of Science ®Google Scholar
• Xu P, Huang S, Zhang H, Mao C, Zhou XE, Cheng X, Simon IA, Shen D-D, Yen H-Y, Robinson CV, et al. Structural insights into the lipid and ligand regulation of serotonin receptors. Nature. 2021;592(7854):469–473.
   PubMed Web of Science ®Google Scholar
• Kimura KT, Asada H, Inoue A, Kadji FMN, Im D, Mori C, Arakawa T, Hirata K, Nomura Y, Nomura N, et al. Structures of the 5-HT2A receptor in complex with the antipsychotics risperidone and zotepine. Nat Struct Mol Biol. 2019;26(2):121–128.
   PubMed Web of Science ®Google Scholar
• Schrödinger release 2021–4: protein preparation wizard. New York (NY): Schrödinger, LLC; 2021.
   Google Scholar
• Madhavi Sastry G, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des. 2013;27(3):221–234.
   PubMed Web of Science ®Google Scholar
• Patel JZ, Parkkari T, Laitinen T, Kaczor AA, Saario SM, Savinainen JR, Navia-Paldanius D, Cipriano M, Leppänen J, Koshevoy IO, et al. Chiral 1,3,4-oxadiazol-2-ones as highly selective FAAH inhibitors. J Med Chem. 2013;56(21):8484–8496.
   PubMed Web of Science ®Google Scholar
• Schrödinger release 2021–4: Glide. New York (NY): Schrödinger, LLC; 2021.
   Google Scholar
• Schrödinger release 2021–4: Maestro. New York (NY): Schrödinger, LLC; 2021.
   Google Scholar
• Duan J, Dixon SL, Lowrie JF, Sherman W. Analysis and comparison of 2D fingerprints: insights into database screening performance using eight fingerprint methods. J Mol Graph Model. 2010;29(2):157–170.
   PubMed Web of Science ®Google Scholar
• Sastry M, Lowrie JF, Dixon SL, Sherman W. Large-scale systematic analysis of 2D fingerprint methods and parameters to improve virtual screening enrichments. J Chem Inf Model. 2010;50(5):771–784.
   PubMed Web of Science ®Google Scholar
• CrysAlis PRO. Version 1.171.37.35g. Yarnton (England): Oxford Diffraction/Agilent Technologies UK Ltd; 2014.
   Google Scholar
• Farrugia LJ. WinGX and ORTEP for Windows: an update. J Appl Crystallogr. 2012;45(4):849–854.
   Web of Science ®Google Scholar
• Sheldrick GM. Crystal structure refinement with SHELXL. Acta Crystallogr C Struct Chem. 2015;71(Pt 1):3–8.
   PubMed Web of Science ®Google Scholar
• Dolomanov OV, Bourhis LJ, Gildea RJ, Howard JAK, Puschmann H. OLEX2: a complete structure solution, refinement and analysis program. J Appl Crystallogr. 2009;42(2):339–341.
   Web of Science ®Google Scholar
• Macrae CF, Sovago I, Cottrell SJ, Galek PTA, McCabe P, Pidcock E, Platings M, Shields GP, Stevens JS, Towler M, et al. Mercury 4.0: from visualization to analysis, design and prediction. J Appl Crystallogr. 2020;53(Pt 1):226–235.
   PubMedGoogle Scholar
• Spek AL. Single-crystal structure validation with the program PLATON. J Appl Crystallogr. 2003;36(1):7–13.
   Web of Science ®Google Scholar
• Kaczor AA, Targowska-Duda KM, Budzyńska B, Biała G, Silva AG, Castro M. In vitro, molecular modeling and behavioral studies of 3-{[4-(5-methoxy-1H-indol-3-yl)-1,2,3,6-tetrahydropyridin-1-yl]methyl}-1,2-dihydroquinolin-2-one (D2AAK1) as a potential antipsychotic. Neurochem Int. 2016;96:84–99.
   PubMed Web of Science ®Google Scholar
• Kondej M, Wróbel TM, Targowska-Duda KM, Leandro Martínez A, Koszła O, Stępnicki P, Zięba A, Paz A, Wronikowska-Denysiuk O, Loza MI, et al. Multitarget derivatives of D2AAK1 as potential antipsychotics: the effect of substitution in the indole moiety. ChemMedChem. 2022;17(15):e202200238.
   PubMed Web of Science ®Google Scholar